Cargando…

Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations

Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported here. Pharmacokinetics over 28 days were assessed i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curley, Paul, Hobson, James J., Liptrott, Neill J., Makarov, Edward, Al-khouja, Amer, Tatham, Lee, David, Christopher A. W., Box, Helen, Neary, Megan, Sharp, Joanne, Pertinez, Henry, Meyers, David, Flexner, Charles, Freel Meyers, Caren L., Poluektova, Larisa, Rannard, Steve, Owen, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383755/ https://www.ncbi.nlm.nih.gov/pubmed/37514020 http://dx.doi.org/10.3390/pharmaceutics15071835

Ejemplares similares

Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
por: Hobson, James J., et al.
Publicado: (2019)

Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants
por: Shakil, Anika, et al.
Publicado: (2022)

Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations
por: Hobson, James J., et al.
Publicado: (2019)

Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.
por: Curley, Paul, et al.
Publicado: (2021)

Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research.
por: Neary, Megan, et al.
Publicado: (2021)

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
por: Tatham, Lee, et al.
Publicado: (2023)

Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
por: Arshad, Usman, et al.
Publicado: (2020)

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis
por: Rajoli, Rajith K. R., et al.
Publicado: (2020)

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
por: Neary, Megan, et al.
Publicado: (2023)

Revealing Donor Substrate-Dependent Mechanistic Control on DXPS, an Enzyme in Bacterial Central Metabolism
por: Johnston, Melanie L., et al.
Publicado: (2021)

DXP Synthase Function in a Bacterial Metabolic Adaptation and Implications for Antibacterial Strategies
por: Chen, Eric C., et al.
Publicado: (2023)

Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation
por: Ibrahim, Ibrahim M, et al.
Publicado: (2019)

Long-Acting Injectable Statins—Is It Time for a Paradigm Shift?
por: Tatham, Lee M., et al.
Publicado: (2019)

Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays
por: Box, Helen, et al.
Publicado: (2022)

Crystallization and preliminary X-ray analysis of the O-methyltransferase NovP from the novobiocin-biosynthetic cluster of Streptomyces spheroides
por: Stevenson, Clare E. M., et al.
Publicado: (2007)

Growth medium-dependent antimicrobial activity of early stage MEP pathway inhibitors
por: Sanders, Sara, et al.
Publicado: (2018)

Identification of an Atg8-Atg3 Protein–Protein Interaction Inhibitor from the Medicines for Malaria Venture Malaria Box Active in Blood and Liver Stage Plasmodium falciparum Parasites
por: Hain, Adelaide U.P., et al.
Publicado: (2014)

Towards a rational design of solid drug nanoparticles with optimised pharmacological properties
por: Siccardi, Marco, et al.
Publicado: (2016)

Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters
por: Gallardo-Toledo, Eduardo, et al.
Publicado: (2023)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Targeting DXP synthase in human pathogens: enzyme inhibition and antimicrobial activity of butylacetylphosphonate
por: Smith, Jessica M., et al.
Publicado: (2013)

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
por: Zhou, Tian, et al.
Publicado: (2017)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Susceptibility of HPV16 and 18 to high level disinfectants indicated for semi‐critical ultrasound probes
por: Ryndock, Eric, et al.
Publicado: (2015)

Advances in nanomedicine drug delivery applications for HIV therapy
por: Curley, Paul, et al.
Publicado: (2017)

Eosinophilic Colitis Associated with Emtricitabine/Tenofovir
por: Lozier, Matthew R, et al.
Publicado: (2018)

Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems
por: Liptrott, Neill J., et al.
Publicado: (2018)

Emtricitabine-induced pure red cell aplasia
por: Manickchund, Nithendra, et al.
Publicado: (2019)

1567 Simplification to elvitegravir/cobicistat/emtricitabine/tenofovir DF from ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir DF maintains HIV suppression and improves fasting triglycerides at week 48
por: Cunningham, Douglas, et al.
Publicado: (2014)

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
por: Patil, Rashmee, et al.
Publicado: (2015)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Tetrazine-mediated bioorthogonal prodrug–prodrug activation
por: Neumann, Kevin, et al.
Publicado: (2018)

Prodrugs and prodrug-activated systems in gene therapy
por: Sheikh, Semira, et al.
Publicado: (2021)

Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug
por: Mori, Giorgia, et al.
Publicado: (2020)

Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy
por: El-Sayed, Ashraf S.A., et al.
Publicado: (2022)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates
por: Chen, Xinhui, et al.
Publicado: (2016)

Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
por: Tanaudommongkon, Asama, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_46gvdvgmd4t2q1hkoflt0tipvs